This paper reports the nature, incidence, and severity of adverse reactions to regimens of rifampicin and ethambutol given once weekly, twice weekly, or daily and to a standard reserve regimen in a total of 330 Chinese failure patients who completed at least six months' chemotherapy in a therapeutic comparison in Hong Kong.
Introduction
There is a large body of evidence that rifampicin in combination with other suitable drugs in daily regimens (Decroix et al., 1969 (Decroix et al., , 1971 Newman et al., 1971; Pines, 1971) , or even when given alone (Nitti, 1969; Lucchesi and Mancini, 1970) , is a potent antituberculosis agent. In-vivo and in-vitro experiments have suggested that it may be even more effective than isoniazid (Canetti et al., 1968) . A number of workers have reported on the efficacy of intermittent rifampicin in animal disease (Grumbach and Rist, 1967; Grumbach et al., 1969 Grumbach et al., , 1970  Verbist, 1969; Batten, 1969 Batten, , 1970 Verbist et al., 1971) , and Dickinson and Mitchison (1970) , in experimental tuberculosis of the guinea-pig, found that to retain equivalent suppression of lesions and reduction of viable counts in the spleen it was not necessary to increase the dose size proportionately as the interval between doses was increased from one to eight days. Suggestions that the increased efficacy with increasing interval between doses can be completely accounted for by the more than proportionate rise in serum concentration which occurs with increasing dose size (Furesz et al., 1967; Constans et al., 1969; Dickinson and Mitchison, 1970) are not supported by the recent work of Dickinson et al. (1972) . Although the mechanisms of action are not yet fully understood, there is now considerable laboratory evidence that rifampicin is a drug which is particularly valuable in fully intermittent regimens.
Rifampicin, when given in conventional daily dosage in man, although highly effective (Decroix et al., 1971) , is very expensive, costing well over £200 for a year's chemotherapy. This makes its use in daily regimens for newly diagnosed cases unrealistic in most developing countries and indeed in many of those that are technically advanced (Fox, 1969) . If an intermittent regimen containing a smaller total weekly dosage which was both therapeutically effective and of low toxicity could be found, the applicability of this valuable drug would be much increased. Furthermore, the level of success achieved with standard reserve regimens in the treatment of failure patients is often disappointingly low (British Tuberculosis Association, 1963; International Union Against Tuberculosis, 1968) . One of the reasons for this is that patients fail to take regularly, for many months, unpleasant daily regimens which can only exceptionally be fully supervised. There is, therefore, an urgent need for reserve regimens which are highly effective, which can be fully supervised on an outpatient basis, which are relatively non-toxic, and which are cheap. All these criteria may be met by intermittent regimens (Fox, 1969 (Fox, , 1971 . For these reasons it was decided to explore in Hong Kong the role of rifampicin in combination with ethambutol in reserve regimen chemotherapy, studying the combination when given daily, twice weekly, and once weekly, the dosages of rifampicin (and ethambutol as well) being increased moderately as the interval between doses increased. Because of the evidence that an initial intensive phase may improve the efficacy of intermittent regimens of other antituberculosis drugs (Tuberculosis Chemotherapy Centre, Madras, 1970) , it was decided to include in the study a regimen in which the once-weekly administration of rifampicin and ethambutol was preceded by a two-month period of daily treatment with these drugs. In order fully to evaluate these four regimens, in terms of both therapeutic efficacy and toxicity, the standard failure regimen of ethionamide, pyrazinamide, and cycloserine used in Hong Kong was also included as an essential control.
Although some workers have encountered no serious toxicity when giving rifampicin plus isoniazid intermittently (Decroix et al., 1971; Verbist et al., 1971) , Poole et al. (1971) , giving the same combination, reported a high incidence of unusual and sometimes serious adverse reactions. Adverse reactions have also been reported with intermittent rifampicin plus ethambutol (Zierski, 1971; Eule, 1971) , and they have also been encountered in the current Hong Kong study. Relatively few patients have yet completed a year of treatment, so the observations reported here are interim ones. The full findings, including the crucial therapeutic results, will be published when all patients have completed their full course of chemotherapy. It is the aim of the present paper to describe the syndromes attributable to intermittent rifampicin which are occurring in the study and to compare the frequency and severity of adverse reactions on the three intermittent rifampicin regimens, on the daily rifampicin regimen, and on the standard reserve regimen. Finally, the ways in which adverse reactions to intermittent rifampicin are now being managed in clinical practice in Hong Kong are described.
Plan and Conduct of the Study PATIENTS ADMITTED TO THE STUDY For the main intake patients with active pulmonary tuberculosis from the six main Government tiibTcrulosis clinics and the four hospitals co-operating were eligible for admission to the study if they were aged 15 years or over, had had at least six months' treatment with standard chemotherapy, including isoniazid plus streptomycin and/or PAS, but had had no treatment with any of the second-line drugs used in the study, had a positive sputum on direct smear examination, and were known to be infected with strains resistant to isoniazid. Patients with non-tuberculous disease which might have been exacerbated by any of the drugs under study were excluded. After a few months a subsidiary group of patients previously treated with ethionamide or pyrazinamide or cycloserine were admitted but were allocated only to the four rifampicin-containing regimens. BRITISH MEDICAL JOURNAL 25 MARCH 1972 REGIMENS In the main intake the patients were allocated at random to one of the following five regimens:
EtZC-the standard reserve regimen for Hong Kong-namely, ethionamide (0 75 or 0 5 g) plus pyrazinamide (2-0 or 1-5 g) plus cycloserine (0-5 g) daily for six months, followed by ethionamide plus pyrazinamide daily, given together in one dose a day.
ER7-ethambutol plus rifampicin daily.
ER2-ethambutol plus rifampicin twice a week.
ER,-ethambutol plus rifampicin once a week.
ER,ER,-ethambutol plus rifampicin daily for two months and then once a week.
The rifampicin dosages, which were given as a single dose, were 450 mg in the daily regimen and in the intermittent regimens, 900 mg for patients weighing less than 90 lb (40 9 kg), 1,050 mg for patients weighing 90-109 lb (40 9-49-5 kg), and 1,200 mg for patients weighing 110 lb (49 9kg) ormore. The dosages of once-weekly rifampicin in the ER, and ER7ER, regimens were originally higher (1,200, 1,500, and 1,800 mg for the three weight classes) but were reduced to the lower schedule seven months after the intake had begun because of the occurrence of adverse reactions. The results for the patients who started once-weekly treatment with the higher dosage schedules, termed the ER7ER, (high) and ER, (high) groups, have been presented separately from the ER7ER, and ER, groups who received the same dosage schedule as the ER, patients.
The ethambutol dosages, given as a single dose, were 25 mg/kg body weight for two months and then 15 mg/kg in the daily regimen, 45 mg/kg per dose in the twice-weekly regimen, and 90 mg/kg per dose in the once-weekly regimen.
Because of the reduction in rifampicin dosage which was made in the once-weekly regimens, the findings for the individual regimens presented in this report are not strictly concurrent.
RECORDING OF ADVERSE REACTIONS
Monthly reports on each patient were sent from Hong Kong to London, giving details of the chemotherapy received during the month, the serum alanine aminotransferase (SGPT) results, and the severity (mild, moderate, or severe) and management of any adverse reactions which had occurred during the month. For the rifampicin-containing regimens special care was taken to clarify any doubts about the nature of symptoms, the frequency or severity of reactions, or their management. Other liver function tests were performed if SGPT levels rose above normal.
MANAGEMENT OF ADVERSE REACTIONS
How the episodes were managed in actual practice is described in the results section. As the study progressed a general pros cedure for managing adverse reactions on intermittent regimenwas evolved. This is described in the discussion. 
Results

INCIDENCE AND TIME OF ONSET OF EPISODES
The cumulative numbers of patients having adverse reactions are given in Table I . On all the regimens adverse reactions occurred even during the first month. By the end of the sixth month the cumulative incidence was similar and low on the ER,, ER2, and ER7ER1 regimens, but substantially higher on the ER1 regimen and the two high-dosage regimens. Thus there was evidence of an association of adverse reactions with the interval between doses and with the dose size of rifampicin, the highest incidence occurring with the once-weekly rifampicin in high dosage. Table II shows the month of onset of the more common syndromes. The onset of most of the cutaneous episodes was during the first month, except in the two high-dosage regimens in which nearly all the episodes started in the first three months. Of the four patients who had the respiratory syndrome, the maximum severity recorded was moderate in two and severe in two.
MANAGEMENT OF ADVERSE REACTIONS
Adverse reactions, in general, proved comparatively easy to manage. Table III (first part) summarizes the changes in chemotherapy which were made to manage episodes of all types.
Of the 60 patients who developed adverse reactions on the intermittent rifampicin regimens, 29 (48%) required no modification of their regimen, 3 (5%) who were among the earliest to develop symptoms responded to a temporary interruption in treatment, 11 (18%) responded to a reduction in rifampicin BRITISH MEDICAL JOURNAL 25 MARCH 1972 dosage, and of the remaining 17, 10 (17%) were able to continue on standard dosage daily rifampicin. In only 7 (12%) was treatment with rifampicin terminated. Of the nine patients who developed adverse reactions among the 74 on the ER, regimen, four required no change in chemotherapy, four responded to a temporary interruption, and only in one was rifampicin terminated. The second part of Table III summarizes the action taken to treat the more common syndromes.
The cutaneous syndrome was usually self-limiting and rarely required anything more than symptomatic treatment. In only one patient, with hypersensitivity to ethambutol as well as to rifampicin during the daily phase of the ER,ER, regimen, was it necessary to change the regimen; this patient had a generalized hypersensitivity reaction with fever, rash, jaundice, enlarged liver, and lymphadenopathy during the second week of treatment.
The abdominal syndrome, when it occurred alone, required only symptomatic treatment. When it occurred simultaneously with other syndromes the records suggest that it was invariably the other syndrome which led to any change in the rifampicin schedule.
The "flu" syndrome occurred on one or more occasions in 40 patients. The episodes stopped spontaneously in 15, in one case they stopped after a temporary interruption of treatment, in 10 cases they ended when the rifampicin dose size had been reduced, in five of these by only one capsule (150 mg), and all except four of the remaining 14 were able to continue on daily rifampicin in conventional dosage.
Of the 14 patients with the "flu" syndrome occurring on its (ER1 (high) ) the rifampicin dosage was reduced because of simultaneous "flu" and abdominal syndromes, in the third (ER,ER, (high)) rifampicin was resumed at full dosage after a six-week interruption, while in the fourth (ER,ER,) rifampicin was resumed after a two-week interruption, but because of simultaneous "flu," abdominal, and respiratory syndromes, it was given daily.
Purpura.-One patient (ER2) developed purpura during the fifth month within an hour of a dose of rifampicin and the platelet count was 112,000/mm3 at three hours. The purpura faded within three days, without arny other evidence of abnormal bleeding, and the platelet count rose to 341,000/mm3. The rifampicin was terminated.
ADVERSE REACTIONS ON CONTROL REGIMEN
Information about the control regimen was taken from the monthly reports and has not been systematically amplified by 769 special correspondence as was that of patients on the rifampicincontaining regimens. Although it may underestimate the incidence of minor side effects, details of the management of episodes were always obtained. The overall incidence (Table I) of side effects (52% ) was high and of the same order as that of the high-dosage rifampicin regimens. More than half the episodes started during the first month. Abdominal and neuropsychiatric symptoms were more common than cutaneous symptoms or arthralgia (Table II) . One patient developed depression (in the fifth month), a second an acute paranoid reaction in the third month, and a third an acute psychosis in the fif-.n month. The six patients with cutaneous reactions all developed generalized itching but only one developed a rash. Of three patients with liver dysfunction one became jaundiced in the fourth month. There was no history of previous liver disease.
Of 28 patients who had adverse reactions (Table III , first part) 18 (64%h) required no change in chemotherapy, and though 10 (36%') had either one drug stopped prematurely or one drug replaced by another, the planned period of triple chemotherapy (six months) was longer than is often prescribed. However, four patients, referred to above, had serious adverse reactionspsychiatric episodes in three and jaundice in one-and all four had the offending drug terminated, as did two others on account of troublesome insomnia in one and paraesthesiae in the other.
ADVERSE REACTIONS STARTING LATER THAN SIX MONTHS
The results given above concern only those episodes which started during the first six months of chemotherapy. Comparisons of the cumulative numbers of episodes at six and at nine months were made for patients who had completed nine months in the study, and at six, nine, and 12 months for those who had completed a year (Table IV) . Most patients who had adverse reactions developed them during the first six months of treatment, though on the intermittent rifampicin regimens the cumulative incidence showed some increase between six and nine months, largely due to episodes of the "flu" syndrome arising for the first time. So far, 118 patients have completed a year of chemotherapy, but there is no evidence in this relatively small number of any appreciable increase in the overall cumulative incidence of adverse reactions between 9 and 12 months.
Three major episodes arose after six months in the 198 patients followed for nine or more months. Two further patients (ER, and ER,ER, (high)) developed purpura in the seventh and ninth months respectively and the rifampicin was terminated. A third (ER,) patient developed jaundice in the eleventh month, necessitating the termination of the rifampicin. There were no more episodes of the respiratory syndrome.
Only three patients on the EtZC regimen developed adverse reactions after six months. (Blajchman et al., 1970; Poole et al., 1971; SepAilveda et al., 1971; Zierski, 1971) or presented at committee meetings (Farga, 1970a (Farga, , 1970b Eule, 1971 ). Most reports have described small numbers of patients and various dosage schedules and rhythms have been studied. The adverse reactions have also been managed in a variety of ways. Poole et al. (1971) not only terminated the rifampicin regimen in patients having reactions but also discontinued it in the rest of the patients under study. Other workers have attempted desensitization for reactions and reduction in dosage (Zierski, 1972) , have continued the same dosage under steroid cover (Zierski, 1972) , or have changed to daily treatment (Eule, 1971; V. Farga, personal communication, 1971 
MANAGEMENT OF ADVERSE REACTIONS
Adverse reactions were most frequent on the once-weekly rifampicin regimens, not only when the rifampicin dosage was high (1,800, 1,500, or 1,200 mg according to body weight) but also when lower (1,200, 1,050, or 900 mg). At these lower dosage levels the incidence was still higher than in the twiceweekly regimen, even though the individual dose size in the latter was the same. Thus both the dose size and the interval between doses are factors that influence the frequency of side effects to intermittent rifampicin. In the event, the reactions were either self-limiting or could almost always be managed either by reducing the dose size or by reducing the interval between doses by changing to daily rifampicin. A procedure for the management of adverse reactions on intermittent rifampicin regimens, evolved during the study, is as follows:
If purpura occurs rifampicin is stopped immediately and is not given again, not even as a small test dose. For the other syndromes the following steps are taken: (1) if an episode severe enough to require more than just simple symptomatic treatment occurs, lowering the dose of rifampicin, usually by one capsule (150 mg) at a time, to a minimum of 600 mg a dose, is tried; and (2) if troublesome symptoms persist an attempt to induce tolerance to rifampicin is made by giving daily doses, usually starting with 150 mg, a dose size which rarely produces symptoms, and increasing by 150 mg a day so that in three days a dose of 450 mg is reached, and this is then continued daily (with daily ethambutol in conventional dosage).
Only in the uncommon event of these procedures failing either to terminate episodes or to make them so trivial or infrequent as to be of no concern to the patient is rifampicin discontinued.
ADVERSE REACTIONS IN PRESENT STUDY
In the present investigation, for 32 of the 60 patients with episodes on intermittent rifampicin, no change in the rifampicin dosage was necessary. In 11 more all that was required was a reduction in the rifampicin dosage and a further 10 were changed to daily rifampicin, which was then continued uneventfully. In (Ferguson, 1971) . Some workers have reported a high incidence of liver dysfunction, including jaundice (Lees et al., 1971) , especially in patients with known liver disease (Lesobre et al., 1969) , while a much lower incidence was reported in a general review of the literature (Bergamini et al., 1971 (Leibold, 1966) . Experience has shown, however, that a lower dosage, although still therapeutically effective, is associated with scarcely any ocular toxicity (Bobrowitz and Robins, 1967 (1971) , who studied 1,200 mg of rifampicin given twice a week, reported a highly significant correlation between the presence of rifampicin-dependent antibodies and the occurrence of adverse reactions. They encountered three cases of thrombocytopenia, one of them with purpura, among the 49 patients treated. However, the risk of purpura cannot now be completely discounted even with daily rifampicin. The occur-rence of circulating antibodies may be one of the reasons for adverse reactions to rifampicin, but it is probable that, in due course, other mechanisms will be shown to be involved. In the Hong Kong study a large programme of immunological and haematological investigations is in progress, among the aims being to identify patients likely to develop adverse reactions and to find ways of preventing such reactions. Clinically, in Hong Kong the problems presented by adverse reactions, as now managed, on intermittent rifampicin regimens are so far not substantially greater than those encountered on the standard reserve regimen, although purpura and the respiratory syndrome require special caution. Even the daily rifampicin regimen cannot be regarded as free from hazard.
In the final analysis a vital issue in the choice of the best failure regimen among those under study will be the relative therapeutic efficacy of the different regimens balanced against the incidence of adverse reactions during the whole period of treatment, and this will be reported on later. In the meantime, reports from other workers on their experience of managing adverse reactions in patients on intermittent rifampicin-containing regimens will be awaited with interest.
